Abstract
New polymer therapeutics like polymer-drug conjugates (PDCs) are developing day by day. Heterocyclic drugs with excellent cytotoxic properties are available, but lack of their specificity makes them available to the normal cells also, which is the main cause of their toxicity. Drugs in the form of PDCs make delivery possible to the specific sites. Most of the PDCs are designed with the aim to either target and/or to get activated in specific cancer microenvironments. Therefore, the most exploited targets for cancer drug delivery are; cancer cell enzymes, heat shock protein 90 (HSP90), multi-drug resistance (MDR) proteins, angiogenesis, apoptosis and cell membrane receptors (e.g., folates, transferrin, etc.). In this review, we will summarize PDCs of heterocyclic drugs, like doxorubicin (DOX), daunorubicin, paclitaxel (PTX), docetaxel (DTX), cisplatin, camptothecin (CPT), geldanamycin (GDM), etc., and some of their analogs for efficient delivery of drugs to cancer cells.
Keywords: Cancer, targeting, endocytosis, angiogenesis, apoptosis, ligand, dendrimer, micelles, block copolymers.
Anti-Cancer Agents in Medicinal Chemistry
Title:Heterocyclic Drug-polymer Conjugates for Cancer Targeted Drug Delivery
Volume: 16 Issue: 11
Author(s): Harmeet Kaur, Sapna D. Desai, Virender Kumar, Pooja Rathi and Jasbir Singh
Affiliation:
Keywords: Cancer, targeting, endocytosis, angiogenesis, apoptosis, ligand, dendrimer, micelles, block copolymers.
Abstract: New polymer therapeutics like polymer-drug conjugates (PDCs) are developing day by day. Heterocyclic drugs with excellent cytotoxic properties are available, but lack of their specificity makes them available to the normal cells also, which is the main cause of their toxicity. Drugs in the form of PDCs make delivery possible to the specific sites. Most of the PDCs are designed with the aim to either target and/or to get activated in specific cancer microenvironments. Therefore, the most exploited targets for cancer drug delivery are; cancer cell enzymes, heat shock protein 90 (HSP90), multi-drug resistance (MDR) proteins, angiogenesis, apoptosis and cell membrane receptors (e.g., folates, transferrin, etc.). In this review, we will summarize PDCs of heterocyclic drugs, like doxorubicin (DOX), daunorubicin, paclitaxel (PTX), docetaxel (DTX), cisplatin, camptothecin (CPT), geldanamycin (GDM), etc., and some of their analogs for efficient delivery of drugs to cancer cells.
Export Options
About this article
Cite this article as:
Kaur Harmeet, Desai D. Sapna, Kumar Virender, Rathi Pooja and Singh Jasbir, Heterocyclic Drug-polymer Conjugates for Cancer Targeted Drug Delivery, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (11) . https://dx.doi.org/10.2174/1871520615666160504094044
DOI https://dx.doi.org/10.2174/1871520615666160504094044 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Advances in Nanomedicines and Targeted Therapies for Colorectal Cancer
Colorectal cancer remains a significant global health challenge, with high incidence and mortality rates despite advancements in treatment strategies. Conventional therapies often face limitations such as systemic toxicity, drug resistance, and suboptimal targeting. The advent of nanomedicines and innovative drug delivery systems offers new hope for overcoming these challenges and ...read more
Discovery of Lead compounds targeting transcriptional regulation
Transcriptional regulation plays key physiological functions in body growth and development. Transcriptional dysregulation is one of the important biomarkers of tumor genesis and progression, which is involved in regulating tumor cell processes such as cell proliferation, differentiation, and apoptosis. Additionally, it plays a pivotal role in angiogenesis and promotes tumor ...read more
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes that aid in stabilizing chromosomal makeup. The resynthesis of telomeres is supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no telomerase activity in human somatic cells, but the stem cells and germ cells undergo ...read more
Innovative targets in medicinal chemistry
Medicinal chemistry continuously evolves in response to emerging healthcare needs and advancements in scientific understanding. This special issue explores the current landscape of innovative targets in medicinal chemistry, highlighting the quest for novel therapeutic avenues. From traditional drug targets such as enzymes and receptors to emerging targets like protein-protein interactions ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
FER1L4: A Long Non-coding RNA with Multiple Roles in the Occurrence and
Development of Tumors
Current Pharmaceutical Design The Role of microRNAs in Gliomas – Therapeutic Implications
Current Molecular Pharmacology Pathophysiological Functions of the lncRNA TUG1
Current Pharmaceutical Design Methods of Preparation of Multifunctional Microbubbles and their In Vitro / In Vivo Assessment of Stability, Functional and Structural Properties
Current Pharmaceutical Design Redox-active and Redox-silent Compounds: Synergistic Therapeutics in Cancer
Current Medicinal Chemistry Recent Advances in Design of Potential Quinoxaline Anti-Infectives
Current Medicinal Chemistry Modulation of Poly(A)-specific Ribonuclease (PARN): Current Knowledge and Perspectives
Current Medicinal Chemistry Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)
Current Drug Targets T Cell Costimulatory and Inhibitory Receptors as Therapeutic Targets for Inducing Anti-Tumor Immunity
Current Cancer Drug Targets Statins and Alkylphospholipids as New Anticancer Agents Targeting Lipid Metabolism
Anti-Cancer Agents in Medicinal Chemistry In Situ Gene Therapy for Prostate Cancer
Current Gene Therapy Germacrone: A Potent Secondary Metabolite with Therapeutic Potential in Metabolic Diseases, Cancer and Viral Infections
Current Drug Metabolism Assessment of Gene Transfer Using Imaging Methodology
Current Genomics Inhibitor at the Gates, Inhibitor in the Chamber: Allosteric and Competitive Inhibitors of the Proteasome as Prospective Drugs
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Environmentally Sensitive Paramagnetic and Diamagnetic Contrast Agents for Nuclear Magnetic Resonance Imaging and Spectroscopy
Current Topics in Medicinal Chemistry Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology Microbial Enzymes used in Prodrug Activation for Cancer Therapy: Insights and Future Perspectives
Current Protein & Peptide Science Synthesis and Evaluation of <sup>198</sup>Au/PAMAM-MPEG-FA against Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry microRNA as Biomarkers and Regulator of Cardiovascular Development and Disease
Current Pharmaceutical Design Discovery of Small Molecules that Target Autophagy for Cancer Treatment
Current Medicinal Chemistry